Diprosone

Legal status and availability in the UK

In our online pharmacy, Diprosone is available without a prescription, with discreet delivery to the United Kingdom in 9–21 days.

Basic Diprosone information

• INN (international nonproprietary name): Betamethasone dipropionate
• Brand names available in the United Kingdom: Diprosone
• ATC code: D07AC01
• Forms and strengths: cream and ointment 0.05%; lotion 0.05%
• OTC / Rx classification: Prescription-only medicine (Rx)

Clinical effectiveness in the UK

How well does betamethasone dipropionate work in everyday NHS practice?

Betamethasone dipropionate 0.05% is effective as a short course (commonly two to four weeks) for severe or resistant psoriasis and certain eczematous flares.

Success is measured by symptom reduction, a shorter time to remission and a lower risk of secondary infection when acute inflammation is controlled.

Ointment formulations are often preferred for chronic plaques while cream formulations are favoured for intertriginous or socially exposed sites.

Indications and expanded uses (MHRA and NHS perspective)

What is it licensed for, and when do dermatologists use it off‑label?

Betamethasone dipropionate is licensed for corticosteroid‑responsive dermatoses and severe or resistant psoriasis.

In clinical practice it is also used for lichen planus, discoid eczema and some hypertrophic inflammatory plaques where short‑term high potency is justified.

Off‑label use occurs in dermatology clinics for recalcitrant localised conditions with specialist oversight.

UK guidance stresses restricting use on the face, flexures and in children, while specialist teams commonly prescribe step‑down regimens from very high to lower potency agents for maintenance.

Use under occlusion or on large surface areas should be avoided except under specialist supervision because of systemic absorption risk.

• Licensed uses: Severe or resistant psoriasis; corticosteroid‑responsive dermatoses.
• Common off‑label uses: Lichen planus, discoid eczema, hypertrophic inflammatory plaques (dermatology use only).

Composition and brand landscape (UK focus)

Which products are available in the UK?

The international nonproprietary name is betamethasone dipropionate and the ATC code is D07AC01, classifying it as a potent topical corticosteroid.

In the UK market there are branded and generic 0.05% cream and ointment presentations, commonly packaged in 15g, 30g and 50g tubes.

Contraindications and special precautions (patient groups)

Who should not use betamethasone dipropionate and who needs extra caution?

Absolute contraindications include hypersensitivity to betamethasone dipropionate or any excipient, and active viral, fungal or tubercular skin infections.

Do not apply near the eyes or on mucous membranes.

Special caution is needed for the elderly because of increased risk of skin thinning, and for patients who are pregnant or breastfeeding where use should be reserved for situations where benefits outweigh risks.

Children under 13 are generally not recommended due to higher systemic absorption risks.

Avoid large‑area or prolonged applications and the use of occlusive dressings unless under specialist supervision, as these increase systemic exposure.

• High‑risk flags checklist: Use on face/flexures, child under 13, application under occlusion, hepatic impairment, prolonged therapy beyond four weeks.

Dosage guidelines (NHS-aligned)

How should patients apply betamethasone dipropionate safely and effectively?

Standard NHS practice is to apply a thin film to affected areas once or twice daily, typically for up to two to four weeks.

Use the shortest effective course and re‑evaluate if there is no response within two weeks.

For the face, flexures and children use lower potency agents and shorter durations where possible.

When treating large plaques advise measured fingertip units to limit surface area and reduce systemic risk.

Specialist regimens commonly step down to a moderate‑potency steroid or a non‑steroidal topical maintenance agent after induction.

• Stepwise regimen examples: Induction with very‑high potency once daily for 1–2 weeks, reassess, then switch to high or moderate potency twice weekly for maintenance as advised by dermatology.
• Fingertip unit guidance: One adult fingertip unit covers approximately two adult handprints; advise patients to measure to avoid excessive area coverage.

Interactions overview (practical MHRA/NHS notes)

Are there drugs or products patients need to avoid while using this cream?

Topical betamethasone dipropionate has minimal direct food or drink interactions.

Clinically relevant interactions involve concurrent systemic corticosteroid therapy, which can add to systemic exposure and HPA‑axis effects.

Other topical agents that thin or irritate skin, such as keratolytics or potent retinoids, may increase percutaneous absorption and so increase risk of systemic effects.

HPA‑axis suppression is more likely when potent topical steroids are used repeatedly, over large areas, or under occlusion.

Caution is recommended when combining with systemic immunosuppressants because of increased infection risk; monitor patients accordingly.

Comparable medicines and prescribing preferences (NHS alternatives)

Which medicines do clinicians pick instead of or after betamethasone dipropionate?

UK formularies include clobetasol propionate as a very‑high potency alternative, and mometasone furoate or diflucortolone as high‑potency options depending on site and severity.

Choice depends on required potency, vehicle tolerability and risk profile; clobetasol can match or exceed potency but carries similar local risk, while mometasone is lower potency and may be chosen for flexural areas.

Dermatology teams usually favour a “potency then step‑down” strategy: induction with a higher potency then maintenance with a lower potency or non‑steroidal therapy.

Frequently asked questions

Can I use it on my face?

Generally no.

Avoid use on the face and eyelids because of the higher risk of skin thinning; a specialist may advise short supervised use if deemed necessary.

How long until it works?

Many patients see symptom relief within days.

Reassess by two weeks and stop by two to four weeks unless advised otherwise by a prescriber.

Is it safe in pregnancy?

Use only if the benefit outweighs the risk and after discussion with your GP or dermatologist.

What if I miss a dose?

Apply as soon as you remember and do not double the next dose.

For quick‑action advice, book a pharmacist consultation if you notice worsening rash, signs of infection, or any new systemic symptoms such as unexpected weight gain or mood changes.

Guidelines for proper use (UK pharmacist counselling style)

What should a pharmacist tell a patient collecting a prescription for betamethasone dipropionate?

Confirm the indication and the prescriber’s intended duration and advise thin‑film application using fingertip units.

Set a clear maximum course of two to four weeks and warn against occlusion and large‑area use unless under specialist instruction.

Explain signs of local adverse effects such as skin thinning, striae and secondary infection and advise urgent review if systemic symptoms (weight gain, mood change) occur.

Provide printed or portal leaflets, document counselling in the NHS record and schedule GP or dermatology review for prolonged need.

Escalate immediately for children, pregnant or breastfeeding patients so the prescriber can reassess risk and benefit.

• Counselling checklist: Confirm indication, demonstrate fingertip unit dosing, set review date, warn about occlusion, advise when to stop and escalate.

Delivery across the United Kingdom